Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.75 USD +1.06% Intraday chart for Vistagen Therapeutics, Inc. -0.21% -7.59%
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI
Apr. 01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI

Evolution of the average Target Price on Vistagen Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e3bddabfc83f7379b9005af29.2P_tW51rjk2-JJYS6XgeaemM2VUeGe6FDmzpgD2YuPI.k5jAaq9a9yfzQKVQkRQrJI_87ydveqyyaTS8xlLXypWfiqQo-SS5fvxT_Q~a941a10a745d037b94f0c76f317affbb

Analyst Recommendations on Vistagen Therapeutics, Inc.

Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6 MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target MT
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating MT
Rate hike fears return with a vengeance Our Logo
Maxim Downgrades VistaGen Therapeutics to Hold From Buy MT
Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8 MT
William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform MT
VISTAGEN THERAPEUTICS : Baird Starts VistaGen Therapeutics at Outperform With $9 Price Target MT
VISTAGEN THERAPEUTICS : Jefferies Starts VistaGen Therapeutics at Buy with $6 Price Target MT
VISTAGEN THERAPEUTICS : William Blair Upgrades VistaGen Therapeutics to Outperform From Market Perform MT
VISTAGEN THERAPEUTICS : Maxim Adjusts Price Target on VistaGen Therapeutics to $5 From $3, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.75 USD
Average target price
13.25 USD
Spread / Average Target
+178.95%
High Price Target
15 USD
Spread / Highest target
+215.79%
Low Price Target
12 USD
Spread / Lowest Target
+152.63%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vistagen Therapeutics, Inc.

Jefferies & Co.
Stifel Nicolaus
Maxim
William Blair & Co.
Baird

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Consensus Vistagen Therapeutics, Inc.